Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The mainstay of moderate to severe Crohn's disease (CD), anti-TNF treatment, shows no clinical benefit in ∼40% of patients, likely due to incomplete cellular targeting and delayed treatment institution. While single-target therapeutics have been highly effective for some CD patients, substantial limitations with respect to safety, efficacy, and long-term, complete remission remain. Deconvolution of the cellular and molecular circuitry of tissue lesions underscores the importance of combinatorial strategies targeting cellular niches. This review aims to evaluate current therapeutic approaches used to manage CD, and highlight recent advances to our cellular, genetic, and molecular understanding of mechanisms driving pathogenic niche activation in CD. We propose new frameworks outlining that combinatorial therapies, along with serial tissue sampling and studies guided by genetics and genomics, can advance on current treatment approaches and will inform newer strategies upon which we can move towards precision therapeutics in IBD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601974 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2021.103690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Less combination therapy and more fistulotomy in perianal fistulizing Crohn's disease in the elderly.
Int J Colorectal Dis
September 2025
Proctology Department, Diaconesses Croix Saint-Simon Hospital Group, 125 Rue d'Avron, 75020, Paris, France.
Background And Aims: This study aimed to describe Crohn's disease perianal fistulizing lesions in patients undergoing surgery over 60 years to compare clinical presentation, management and outcomes with those observed in younger patients.
Methods: Between January 2012 and December 2022, all patients over 60 years old who underwent a first surgical intervention for anal fistula at two medical centers were included. For each patient included, two younger patients who underwent the same surgical procedure during the same period in the same centers were matched for comparison.
Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab.
Dig Liver Dis
September 2025
Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Cincinnati Children's Hospital Medical Center and the University of Cin
Background And Aims: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development.
Methods: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024.
Infliximab and ustekinumab clearance better predict endoscopic outcomes than trough concentrations in Crohn's disease.
Clin Gastroenterol Hepatol
September 2025
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address:
Background And Aims: Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD).
Methods: Data from patients with moderate-to-severe CD starting infliximab (n=108) and ustekinumab (n=80) therapy were repurposed.
Fatigue in patients with Inflammatory Bowel Disease: a descriptive cross-sectional study.
Gastroenterol Hepatol
September 2025
Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI) Hospital General Universitario Gregorio Marañón, Calle Francisco Silvela 40, 28028 Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Calle del Doctor Esquerdo nº 46, 28009 Madrid, España; Depa
Aim: To identify factors associated with the presence of fatigue in patients with inflammatory bowel disease.
Patients And Method: Prospective cross-sectional descriptive study conducted in a multidisciplinary centre for the treatment of EIMI. Participants were patients diagnosed with IBD under follow-up in an advanced practice nurse (APN) consultation.
A child with ulcerative colitis presenting with delirium: a case report.
Turk J Pediatr
September 2025
Department of Pathology, University of Health Sciences Antalya Education and Research Hospital, Antalya, Türkiye.
Background: Delirium in patients with ulcerative colitis may be seen, especially in the elderly and in patients hospitalized for a long time. In children, Wernicke's encephalopathy may occur due to thiamine deficiency in both ulcerative colitis and Crohn's disease. We present a patient with ulcerative colitis who presented with delirium as the first symptom, did not respond to steroid treatment and improved with anti-tumor necrosis factor-alpha treatment.
View Article and Find Full Text PDF